ArticleJournal of the American Heart Association2016
Irisin Inhibits Atherosclerosis by Promoting Endothelial Proliferation Through microRNA126-5p.
Article in Journal of the American Heart Association, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 1 synthesis or guideline pooled it, 75 citations in OpenAlex.
- Preclinical techniques to investigate exercise training in vascular pathophysiology.American journal of physiology. Heart and circulatory physiology · 2021Pooled it
- PGC-1β Mediates the Atheroprotective Roles of β-Aminoisobutyric Acid (BAIBA) in Vascular Endothelial Cells.Journal of atherosclerosis and thrombosis · 2026Article
- Lean body mass index and hypertension risk in men: a nationwide epidemiological cohort study.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Article
- Impacts of systemic milieu on cerebrovascular and brain aging: insights from heterochronic parabiosis, blood exchange, and plasma transfer experiments.GeroScience · 2025Review
- Skeletal Muscle as a Mediator of Interorgan Crosstalk During Exercise: Implications for Aging and Obesity.Circulation research · 2025Review
- Are breast milk and serum irisin levels affected by the BMI and nutritional status? A prospective observational study.European journal of pediatrics · 2025Observational
- Expression and Clinical Significance of Irisin in Serum and Placenta Tissues of Pregnant Women with Severe Preeclampsia.International journal of women's health · 2025Article
- Disturbance in the potential cardiovascular-bone-skeletal muscle axis and morbidity and mortality in patients undergoing haemodialysis: the Q-Cohort Study.Clinical kidney journal · 2024Article
- Hydrogen Sulfide and Irisin, Potential Allies in Ensuring Cardiovascular Health.Antioxidants (Basel, Switzerland) · 2024Review
- Review
- FNDC5 genetic polymorphism in patients with peripartum cardiomyopathy.Caspian journal of internal medicine · 2024Article
- The emerging roles of irisin in vascular calcification.Frontiers in endocrinology · 2024Review
- Irisin: A Potentially Fresh Insight into the Molecular Mechanisms Underlying Vascular Aging.Aging and disease · 2023Review
- Irisin Regulates Cardiac Responses to Exercise in Health and Diseases: a Narrative Review.Journal of cardiovascular translational research · 2023Review
- Astaxanthin Alleviates Foam Cell Formation and Promotes Cholesterol Efflux in Ox-LDL-Induced RAW264.7 Cells via CircTPP2/miR-3073b-5p/ABCA1 Pathway.Molecules (Basel, Switzerland) · 2023Article
- Irisin Ameliorates Renal Tubulointerstitial Fibrosis by Regulating the Smad4/β-Catenin Pathway in Diabetic Mice.Diabetes, metabolic syndrome and obesity : targets and therapy · 2023Article
- Effects of the Myokine Irisin on Stromal Cells from Swine Adipose Tissue.Biomolecules · 2022Article
- Irisin, an Effective Treatment for Cardiovascular Diseases?Journal of cardiovascular development and disease · 2022Review
- Emerging cross-talks between chronic kidney disease-mineral and bone disorder (CKD-MBD) and malnutrition-inflammation complex syndrome (MICS) in patients receiving dialysis.Clinical and experimental nephrology · 2022Review
- Irisin-Associated Neuroprotective and Rehabilitative Strategies for Stroke.Neuromolecular medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIrisin is a newly discovered myokine that has been considered a promising candidate for the treatment of cardiovascular disease through improving endothelial function. However, little is known about the role of irisin in the progression of atherosclerosis. METHODS AND
resultsWe used a carotid partial ligation model of apolipoprotein E-deficient mice fed on a high-cholesterol diet to test the anti-atherosclerosis effect of irisin. Irisin treatment significantly suppressed carotid neointima formation. It was associated with increased endothelial cell proliferation. In addition, irisin promoted human umbilical vein endothelial cell survival via upregulating microRNA126-5p expression through the ERK signaling pathway. Inhibition of microRNA126-5p using the microRNA126-5p inhibitor abolished the prosurvival effect. The same results were demonstrated in vivo as the expression of microRNA126-5p noticeably increased in ligated carotid artery after irisin treatment. Furthermore, in vivo blockade of microRNA126-5p expression using the antagomir abolished the inhibitory effects of irisin on neointima formation, lesional lipid deposition, macrophage area, and the pro-proliferation effects on endothelial cells.
conclusionsTaken together, our study demonstrates that irisin significantly reduces atherosclerosis in apolipoprotein E-deficient mice via promoting endothelial cell proliferation through microRNA126-5p, which may have a direct therapeutic effect on atherosclerotic diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.